Regeneron Pharmaceuticals (REGN) Non-cash Items (2009 - 2026)

Regeneron Pharmaceuticals' Non-cash Items history runs 18 years deep, the most recent figure standing at $351.7 million for Q1 2026.

• In Q1 2026, Non-cash Items rose 48.77% year-over-year to $351.7 million; the TTM figure through Mar 2026 stood at $589.3 million (up 207.89% YoY), while the FY2025 annual figure was $474.0 million, up 5900.0% from the prior year.
• Non-cash Items was $351.7 million for Q1 2026 at Regeneron Pharmaceuticals, up from $326.1 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $1.1 billion in Q1 2022 to a low of -$1.1 billion in Q2 2024.
• Historically, Non-cash Items has averaged $126.5 million across 5 years, with a median of $158.7 million in 2025.
• Biggest YoY gain for Non-cash Items was 593.71% in 2024; the steepest drop was 2096.85% in 2024.
• A 5-year view of Non-cash Items shows it stood at $522.8 million in 2022, then plunged by 113.37% to -$69.9 million in 2023, then surged by 593.71% to $345.1 million in 2024, then decreased by 5.51% to $326.1 million in 2025, then advanced by 7.85% to $351.7 million in 2026.
• The last three Non-cash Items figures came in at $351.7 million (Q1 2026), $326.1 million (Q4 2025), and $158.7 million (Q3 2025), per Business Quant data.